Literature DB >> 23620000

Comparable long-term outcomes after reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for adult high-risk acute lymphoblastic leukemia in complete remission.

Ki-Seong Eom1, Seung-Hwan Shin, Jae-Ho Yoon, Seung-Ah Yahng, Sung-Eun Lee, Byung-Sik Cho, Yoo-Jin Kim, Hee-Je Kim, Chang-Ki Min, Dong-Wook Kim, Jong-Wook Lee, Woo-Sung Min, Chong-Won Park, Seok Lee.   

Abstract

The role of reduced-intensity conditioning (RIC) in adult acute lymphoblastic leukemia (ALL) remains unclear because of the small sample size, short follow-up duration, various regimens for conditioning and graft-versus-host disease (GVHD) prophylaxis, and the heterogeneity of selection criteria for transplantation. We compared long-term outcomes of 60 consecutive RIC transplants (fludarabine plus melphalan) with 120 myeloablative conditioning (MAC) transplants (total body irradiation plus cyclophosphamide) for adult high-risk ALL in first or second complete remission. All transplants received a uniform strategy of pretransplant chemotherapy and GVHD prophylaxis. Compared to MAC transplants, RIC transplants had older age (46 years vs. 33 years, P < 0.001) and higher proportions of transplantation using peripheral blood (93.3% vs. 13.3%; P < 0.001) but otherwise showed similar characteristics. After a median follow-up of 67 months, RIC transplants showed comparable nonrelapse mortality (21.2% vs. 24.3%) and disease-free survival (50.8% vs. 54.9%) to MAC transplants, although relapse risk was higher (34.2% vs. 26.4%; HR, 2.07; P = 0.019) in multivariate analysis. Other independent factors associated with better outcomes were the presence of chronic GVHD and transplantation in first complete remission. Interestingly, the negative impact of RIC on relapse risk was seen only for Philadelphia-positive ALL transplants (32.7% vs. 19.6%; HR, 3.46; P = 0.020), while no difference was found between RIC and MAC for Philadelphia-negative ALL transplants (35.0% vs. 32.1%; HR, 1.39; P = 0.429). RIC can be considered as a reasonable choice for providing a sufficient long-term graft-versus-leukemia effect for adult high-risk ALL patients ineligible for MAC.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23620000     DOI: 10.1002/ajh.23465

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  14 in total

1.  Marrow damage and hematopoietic recovery following allogeneic bone marrow transplantation for acute leukemias: Effect of radiation dose and conditioning regimen.

Authors:  Christopher Wilke; Shernan G Holtan; Leslie Sharkey; Todd DeFor; Mukta Arora; Priya Premakanthan; Sophia Yohe; Stefano Vagge; Daohong Zhou; Jennifer L Holter Chakrabarty; Marc Mahe; Renzo Corvo; Kathryn Dusenbery; Guy Storme; Daniel J Weisdorf; Michael R Verneris; Susanta Hui
Journal:  Radiother Oncol       Date:  2015-11-30       Impact factor: 6.280

2.  Effects of conditioning intensity in allogeneic stem cell transplantation for Philadelphia chromosome‑positive acute lymphoblastic leukemia.

Authors:  Shuichiro Takashima; Toshihiro Miyamoto; Tomohiko Kamimura; Goichi Yoshimoto; Shuro Yoshida; Hideho Henzan; Ken Takase; Koji Kato; Yoshikiyo Ito; Yuju Ohno; Koji Nagafuji; Tetsuya Eto; Takanori Techima; Koichi Akashi
Journal:  Int J Hematol       Date:  2015-12       Impact factor: 2.490

3.  Reduced-intensity conditioning is a reasonable alternative for Philadelphia chromosome-positive acute lymphoblastic leukemia among elderly patients who have achieved negative minimal residual disease: a report from the Adult Acute Lymphoblastic Leukemia Working Group of the JSHCT.

Authors:  Yu Akahoshi; Satoshi Nishiwaki; Yasuyuki Arai; Kaito Harada; Yuho Najima; Yoshinobu Kanda; Katsuhiro Shono; Shuichi Ota; Takahiro Fukuda; Naoyuki Uchida; Souichi Shiratori; Masatsugu Tanaka; Junji Tanaka; Yoshiko Atsuta; Shinichi Kako
Journal:  Bone Marrow Transplant       Date:  2020-05-23       Impact factor: 5.483

4.  Experience of blinatumomab salvage for patients with acute lymphoblastic leukemia presenting with isolated extramedullary relapse after previous allogeneic hematopoietic cell transplantation.

Authors:  Seug Yun Yoon; Jae-Ho Yoon; Gi June Min; Sung-Soo Park; Silvia Park; Sung-Eun Lee; Byung-Sik Cho; Ki-Seong Eom; Yoo-Jin Kim; Hee-Je Kim; Chang-Ki Min; Seok-Goo Cho; Jong Wook Lee; Seok Lee
Journal:  Bone Marrow Transplant       Date:  2019-10-07       Impact factor: 5.483

Review 5.  Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia in Adults.

Authors:  Craig Speziali; Kristjan Paulson; Matthew Seftel
Journal:  Curr Hematol Malig Rep       Date:  2016-06       Impact factor: 3.952

Review 6.  Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation.

Authors:  S R Pingali; R E Champlin
Journal:  Bone Marrow Transplant       Date:  2015-05-18       Impact factor: 5.483

7.  Impact of IKZF1 deletions on long-term outcomes of allo-SCT following imatinib-based chemotherapy in adult Philadelphia chromosome-positive ALL.

Authors:  M Kim; J Park; D-W Kim; Y-J Kim; Y-W Jeon; J-H Yoon; S-H Shin; S-A Yahng; S-E Lee; B-S Cho; K-S Eom; H-J Kim; C-Ki Min; S-G Cho; Y Kim; J-W Lee; K Han; W-S Min; S Lee
Journal:  Bone Marrow Transplant       Date:  2014-12-15       Impact factor: 5.483

8.  Impact of donor type on long-term graft-versus-host disease-free/relapse-free survival for adult acute lymphoblastic leukemia in first remission.

Authors:  Jae-Ho Yoon; Gi June Min; Sung-Soo Park; Silvia Park; Sung-Eun Lee; Byung-Sik Cho; Ki-Seong Eom; Yoo-Jin Kim; Hee-Je Kim; Chang-Ki Min; Seok-Goo Cho; Jong-Wook Lee; Seok Lee
Journal:  Bone Marrow Transplant       Date:  2020-10-30       Impact factor: 5.483

9.  PBSC vs BM grafts with myeloablative conditioning for unrelated donor transplantation in adults with high-risk ALL.

Authors:  S-H Shin; J-H Yoon; S-A Yahng; S-E Lee; B-S Cho; K-S Eom; Y-J Kim; H-J Kim; C-K Min; S-G Cho; D-W Kim; J-W Lee; W-S Min; C-W Park; S Lee
Journal:  Bone Marrow Transplant       Date:  2014-03-24       Impact factor: 5.483

10.  Reduced intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemia.

Authors:  Veronika Bachanova; Wael Saber; Ashley Rosko; Hai-Lin Wang; Marcos de Lima; Brenda Sandmaier; H Jean Khoury; Andrew Artz; Johnathan Brammer; Christopher Bredeson; Sherif Farag; Mohamed Kharfan-Dabaja; Hillard M Lazarus; David I Marks; Rodrigo Martino Bufarull; Joseph McGuirk; Mohamed Mohty; Taiga Nishihori; Ian Nivison-Smith; Armin Rashidi; Olle Ringden; Matthew Seftel; Daniel Weisdorf
Journal:  Am J Hematol       Date:  2016-11-12       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.